Digital Companion Diagnostics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509240862

Publication Date:

September 13, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

A companion diagnostic is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The test helps a health care professional determine whether a particular therapeutic product鈥檚 benefits to patients will outweigh any potential serious side effects or risks.Digital Companion Diagnostics (CD) refer to a type of in vitro diagnostic tests or assays that are intended to help physicians in making effective treatment decisions based on the patient鈥檚 response to a specific drug targeted toward a specific biomarker, expressed in a particular disease or indication. The patient鈥檚 response to an ongoing therapy is mapped with the help of companion diagnostics in terms of changes in gene amplification, nullifying the effect of mutations, changes in protein overexpression and receptor-substrate interaction, and so on.
The global market for Digital Companion Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Digital Companion Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Digital Companion Diagnostics by region & country, by Type, and by Application.
The Digital Companion Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Digital Companion Diagnostics.
麻豆原创 Segmentation
By Company
Myriad Genetic Laboratories, Inc.
Qiagen Manchester, Ltd.
Roche
Dako North America
Abbott
ICON plc
Illumina, Inc
Thermo Fisher
Segment by Type:
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Next Generation Sequencing (NGS)
Segment by Application
Breast Cancer
Melanoma
Lung Cancer
Colorectal Cancer
Infectious Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Digital Companion Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Digital Companion Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Digital Companion Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Digital Companion Diagnostics Product Introduction
1.2 Global Digital Companion Diagnostics 麻豆原创 Size Forecast
1.3 Digital Companion Diagnostics 麻豆原创 Trends & Drivers
1.3.1 Digital Companion Diagnostics Industry Trends
1.3.2 Digital Companion Diagnostics 麻豆原创 Drivers & Opportunity
1.3.3 Digital Companion Diagnostics 麻豆原创 Challenges
1.3.4 Digital Companion Diagnostics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Digital Companion Diagnostics Players Revenue Ranking (2023)
2.2 Global Digital Companion Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies Digital Companion Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Digital Companion Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Digital Companion Diagnostics
2.6 Digital Companion Diagnostics 麻豆原创 Competitive Analysis
2.6.1 Digital Companion Diagnostics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Digital Companion Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Digital Companion Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Polymerase Chain Reaction (PCR)
3.1.2 Immunohistochemistry (IHC)
3.1.3 In Situ Hybridization (ISH)
3.1.4 Next Generation Sequencing (NGS)
3.2 Global Digital Companion Diagnostics Sales Value by Type
3.2.1 Global Digital Companion Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Digital Companion Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global Digital Companion Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Breast Cancer
4.1.2 Melanoma
4.1.3 Lung Cancer
4.1.4 Colorectal Cancer
4.1.5 Infectious Disease
4.1.6 Others
4.2 Global Digital Companion Diagnostics Sales Value by Application
4.2.1 Global Digital Companion Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Digital Companion Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global Digital Companion Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Digital Companion Diagnostics Sales Value by Region
5.1.1 Global Digital Companion Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Digital Companion Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global Digital Companion Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global Digital Companion Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Digital Companion Diagnostics Sales Value, 2019-2030
5.2.2 North America Digital Companion Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Digital Companion Diagnostics Sales Value, 2019-2030
5.3.2 Europe Digital Companion Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Digital Companion Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific Digital Companion Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Digital Companion Diagnostics Sales Value, 2019-2030
5.5.2 South America Digital Companion Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Digital Companion Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Digital Companion Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Digital Companion Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Digital Companion Diagnostics Sales Value
6.3 United States
6.3.1 United States Digital Companion Diagnostics Sales Value, 2019-2030
6.3.2 United States Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Digital Companion Diagnostics Sales Value, 2019-2030
6.4.2 Europe Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Digital Companion Diagnostics Sales Value, 2019-2030
6.5.2 China Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Digital Companion Diagnostics Sales Value, 2019-2030
6.6.2 Japan Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Digital Companion Diagnostics Sales Value, 2019-2030
6.7.2 South Korea Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Digital Companion Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Digital Companion Diagnostics Sales Value, 2019-2030
6.9.2 India Digital Companion Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Digital Companion Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Myriad Genetic Laboratories, Inc.
7.1.1 Myriad Genetic Laboratories, Inc. Profile
7.1.2 Myriad Genetic Laboratories, Inc. Main Business
7.1.3 Myriad Genetic Laboratories, Inc. Digital Companion Diagnostics Products, Services and Solutions
7.1.4 Myriad Genetic Laboratories, Inc. Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 Myriad Genetic Laboratories, Inc. Recent Developments
7.2 Qiagen Manchester, Ltd.
7.2.1 Qiagen Manchester, Ltd. Profile
7.2.2 Qiagen Manchester, Ltd. Main Business
7.2.3 Qiagen Manchester, Ltd. Digital Companion Diagnostics Products, Services and Solutions
7.2.4 Qiagen Manchester, Ltd. Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 Qiagen Manchester, Ltd. Recent Developments
7.3 Roche
7.3.1 Roche Profile
7.3.2 Roche Main Business
7.3.3 Roche Digital Companion Diagnostics Products, Services and Solutions
7.3.4 Roche Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 Dako North America Recent Developments
7.4 Dako North America
7.4.1 Dako North America Profile
7.4.2 Dako North America Main Business
7.4.3 Dako North America Digital Companion Diagnostics Products, Services and Solutions
7.4.4 Dako North America Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 Dako North America Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Digital Companion Diagnostics Products, Services and Solutions
7.5.4 Abbott Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Recent Developments
7.6 ICON plc
7.6.1 ICON plc Profile
7.6.2 ICON plc Main Business
7.6.3 ICON plc Digital Companion Diagnostics Products, Services and Solutions
7.6.4 ICON plc Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 ICON plc Recent Developments
7.7 Illumina, Inc
7.7.1 Illumina, Inc Profile
7.7.2 Illumina, Inc Main Business
7.7.3 Illumina, Inc Digital Companion Diagnostics Products, Services and Solutions
7.7.4 Illumina, Inc Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 Illumina, Inc Recent Developments
7.8 Thermo Fisher
7.8.1 Thermo Fisher Profile
7.8.2 Thermo Fisher Main Business
7.8.3 Thermo Fisher Digital Companion Diagnostics Products, Services and Solutions
7.8.4 Thermo Fisher Digital Companion Diagnostics Revenue (US$ Million) & (2019-2024)
7.8.5 Thermo Fisher Recent Developments
8 Industry Chain Analysis
8.1 Digital Companion Diagnostics Industrial Chain
8.2 Digital Companion Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Digital Companion Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Digital Companion Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Myriad Genetic Laboratories, Inc.
Qiagen Manchester, Ltd.
Roche
Dako North America
Abbott
ICON plc
Illumina, Inc
Thermo Fisher

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.